The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
Open accessAbstract
Importance: In a comparative clinical study with progression-free survival (PFS) or overall survival (OS) as the end point, the hazard ratio (HR) is routinely used to design the study and to estimate the treatment effect at the end of the study. The clinical interpretation of the HR may not be straightforward, especially when the underlying model assumption is not valid. A robust procedure for study design and analysis that enables clinically meaningful interpretation of trial results is warranted. Objective: To discuss issues of conventional trial design and analysis and to present alternatives to the HR using a recent immunotherapy study as an illustrative example. Design, Setting, and Participants: By comparing 2 groups in a survival analysis, we discuss issues of using the HR and present the restricted mean survival time (RMST) as a summary measure of patients’ survival profile over time. We show how to use the difference or ratio in RMST between 2 groups as an alternative for designing and analyzing a clinical study with an immunotherapy study as an illustrative example. Main Outcomes and Measures: Overall survival or PFS. Group contrast measures included HR, RMST difference or ratio, and the event rate difference. Results: For the illustrative example, the HR procedure indicates that nivolumab significantly prolonged patient OS and was numerically better than docetaxel for PFS. However, the median PFS time of docetaxel was significantly better than that of nivolumab. Therefore, it may be difficult to use median OS and/or PFS to interpret of the HR value clinically. On the other hand, using RMST difference, nivolumab was significantly better than docetaxel for both OS and PFS. We also provide details regarding design of a future study with RMST-based measures. Conclusions and Relevance: The design and analysis of a conventional cancer clinical trial can be improved by adopting a robust statistical procedure that enables clinically meaningful interpretations of the treatment effect. The RMST-based quantitative method may be used as a primary tool for future cancer trials or to help us to better understand the clinical interpretation of the HR even when its model assumption is plausible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Guyot, P., Ades, A., Ouwens, M. J., & Welton, N. J. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-9 · Cited by 2,526
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Royston, P., & Parmar, M. K. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-152 · Cited by 1,062
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Uno, H., Claggett, B., Tian, L., Inoue, E., Gallo, P., Miyata, T., Schrag, D., Takeuchi, M., Uyama, Y., Zhao, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2208 · Cited by 810
Self-citationA resampling method based on pivotal estimating functions
PARZEN, M. I., WEI, L. J., & YING, Z. (1994) · Biometrika · doi:10.1093/biomet/81.2.341 · Cited by 288
Self-citationTrinquart, L., Jacot, J., Conner, S. C., & Porcher, R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2488 · Cited by 251
Uno, H., Wittes, J., Fu, H., Solomon, S. D., Claggett, B., Tian, L., Cai, T., Pfeffer, M. A., Evans, S. R., & Wei, L.-J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1741 · Cited by 220
Self-citationA Conversation with Sir David Cox
Reid, N. (1994) · Statistical Science · doi:10.1214/ss/1177010394 · Cited by 173
Péron, J., Roy, P., Ozenne, B., Roche, L., & Buyse, M. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6359 · Cited by 63
Li, J., Zhao, L., Tian, L., Cai, T., Claggett, B. L., Callegaro, A., Dizier, B., Spiessens, B., Ulloa‐Montoya, F., & Wei, L. J. (2015) · Biometrics · doi:10.1111/biom.12461 · Cited by 54
Self-citation
Cited by
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
Why Test for Proportional Hazards?
Stensrud, M. J., & Hernán, M. A. (2020) · JAMA · doi:10.1001/jama.2020.1267 · Cited by 532
Huang, C., Liu, H., Hu, Y., Sun, Y., Su, X., Cao, H., Hu, J., Wang, K., Suo, J., Tao, K., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2021.5104 · Cited by 270
Metadata
- Authors
- Pak, K., Uno, H., Kim, D. H., Tian, L., Kane, R. C., Takeuchi, M., Fu, H., Claggett, B., & Wei, L.-J.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-12-01
- Volume
- 3
- Issue
- 12
- Pages
- 1692
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2760699482
- Cited by
- 269
- References
- 14
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.